Calabrese J R, Fatemi S H, Kujawa M, Woyshville M J
Department of Psychiatry, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Ohio, USA.
J Clin Psychopharmacol. 1996 Apr;16(2 Suppl 1):24S-31S. doi: 10.1097/00004714-199604001-00004.
Although lithium remains the preferred treatment of bipolar disorder, only 60 to 80% of patients with the classic presentation have an adequate response to this drug. When the response rate to lithium is considered across the entire spectrum of bipolar disorders, this rate probably decreases to 50%. Natural history, illness subtype, and comorbidity are all important general predictors of response to treatment. At present, the only predictors that seem to differentially favor divalproex, and possible, carbamazepine over lithium are mixed states and rapid cycling. An overview of clinical presentations that predict general and differential response to mood stabilizers is provided.
尽管锂盐仍然是双相情感障碍的首选治疗药物，但只有60%至80%的典型症状患者对该药物有充分反应。当考虑双相情感障碍全谱对锂盐的反应率时，这一比率可能降至50%。自然病程、疾病亚型和共病都是治疗反应的重要总体预测因素。目前，似乎比锂盐更有利于丙戊酸，可能还有卡马西平的唯一预测因素是混合状态和快速循环。本文提供了预测对心境稳定剂的总体和差异反应的临床表现概述。
